Instylla, Inc. appears in FDA premarket approval records as the applicant for the Embrace Hydrogel Embolic System, an embolization agent for the vascular system classified as a Class III device under product code QVG. The original PMA, P250003, was received on February 6, 2025 and approved on August 5, 2025, with the FDA advisory committee listed as Cardiovascular. The supplied filings show a single device family moving through supplements rather than a broad catalogue, and the company's own site discusses transcatheter embolization as the clinical context for its product. [5][6][7]

Documented product and stated indication

The Embrace Hydrogel Embolic System is described in the FDA summary of safety and effectiveness data as an embolization agent, vascular, with the trade name Embrace Hydrogel Embolic System (HES). The original approval statement covers embolization of hypervascular tumors in peripheral arteries at or above 5mm. A later labeling supplement, S008, records an expanded indication statement covering hypervascular tumors in peripheral arteries at or above 5mm and peripheral arterial bleeds in vessels at or above 6mm. [5][6][1]

Instylla's own website frames the clinical need around transcatheter embolization, describing catheter-directed embolic agents delivered to close off vessels supplying blood to a tumor, and lists shortcomings it attributes to existing embolization treatments, including incomplete penetration of the tumor vascular bed and flow into healthy vessels. Those statements are the company's published characterization of the field, not independently verified performance data for Embrace. [7]

Supplement activity in the supplied filings

The supplied collection holds five linked PMA records for P250003, with decision counts of four approvals and one 30-day notice as of the snapshot date. The record sample is the same five entries, so the sample counts match the collection counts here. Beyond the original approval, the sample includes S008, a Panel Track labeling change received April 28, 2026 and approved October 23, 2026; S010, a Special (Immediate Track) process change covering repositioning of the product within the pouch before moist heat sterilization of the precursor kit, received September 21, 2026 and approved October 21, 2026; and S011, a Special (Immediate Track) process change received September 29, 2026 and approved October 23, 2026. [1][3][2]

S009 was a 30-Day Notice for a change in minimum packaging configuration, received August 17, 2026 and decided September 3, 2026. Read together, the supplements concern labeling, packaging configuration and manufacturing process details rather than new clinical indications beyond the S008 labeling change. The filings do not disclose sales, market uptake or post-market clinical results. [4][1]

Regulatory posture and what remains unknown

Every supplied record lists the applicant as Instylla, Inc. at 201 Burlington Rd., North Building, Bedford, MA, with the Cardiovascular advisory committee and no expedited review flag. The SSED notes that no panel recommendation was recorded and references compliance with the device Quality System regulation at 21 CFR 820. No parent company, brand owner or corporate affiliate is verified in these sources, and the applicant should not be conflated with any unlisted entity. [5][6][2]

Several details remain unknown from the public information: the company's actual headquarters, ownership structure, commercial availability, customer base and any clinical outcome measures. The FDA filing address is an address of record and cannot be treated as a headquarters. The company site's discussion of embolization shortcomings is a publisher's statement about the category, and no source here reports firsthand testing or comparative efficacy for Embrace. [7][6]